United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting
For best results when printing this announcement, please click on link below: United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting A pre-specified subgroup analysis from the phase 3 ADVANCE OUTCOMES study showed that ralinepag reduced the risk of clinical worsening in patients with pulmonary arterial